Australian biotech market watch 19/03/10
Friday, 19 March, 2010
At the end of a buoyant week for the stock market, the All Ordinaries is flat as of midday today, up a marginal 6.5 points to 4,884.20.
After Cochlear (ASX:COH) announced a change of chairman as Tommie Bergman indicated he was to step down, stocks in the company have seen a bump, up 3.86% since the announcement to $69.30 today.
Two of the other Big Three have remained fairly steady, with CSL (ASX:CSL) hovering around the $36 mark and ResMed loitering around $6.73.
Xenotransplantation specialists, Living Cell Technology (ASX:LCT), saw a steep rise early in the week, but much of the gains have been lost Thursday and today, with it dropping 2c to 21c, although that's still above the sub-20c mark it was trading at last week.
Mesoblast (ASX:MSB) is fairly steady today, up 1c to $2.06, but saw a tidy 5% lift in yesterday's trading.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
